

MRD in NSCLC

Supplementary Table 1. Baseline characteristic measurements

| Characteristics | N | % |
|---|---|---|
| Total | | |
| Gender | | |
| Male | | |
| Female | | |
| Age | | |
| > 60 | | |
| < 60 | | |
| Smoking | | |
| Yes | | |
| No | | |
| Histology | | |
| Squamous-cell carcinoma | | |
| Adenocarcinoma | | |
| Adeno-squamous carcinoma | | |
| Large cell carcinoma | | |
| Stage | | |
| IA1 | | |
| IA2 | | |
| IA3 | | |
| IB | | |
| IIA | | |
| EGFR mutation | | |
| Without (EGFR-) | | |
| With (EGFR+) | | |
| Subtypes of EGFR mutation | | |
| EGFR exon 19 deletion (19del) | | |
| EGFR L858R | | |
| G719A/C/S | | |
| S768I | | |
| Others (N468K, E709A, N771delinsGY, H870R, P772_H773dup, I740_K745dup, V774M, A767_V769dup, R451H, D761Y and amplification) | | |
| At least two EGFR mutation subtypes | | |
| ctDNA analysis | | |
| Negative | | |
| Positive | | |
| Postoperative therapy (Adjuvant therapy) | | |
| Targeted therapy | | |
| Chemotherapy | | |